Table 1.
Patient demographic and baseline characteristics.
| Whole sample (n = 427) | Gem-Nab (n = 219) | Gem (n = 208) | P value | ||
|---|---|---|---|---|---|
| Median age (min; max) | 63 (30–80) | 63 (33–79) | 63 (30–80) | 0.62 | |
| Age category | Age <65 | 267 (62.53%) | 135 (61.64%) | 132 (63.46%) | 0.69 |
| Age ≥65 | 160 (37.47%) | 84 (38.36%) | 76 (36.54%) | ||
| Sex | Women | 191 (44.73%) | 99 (45.21%) | 92 (44.23%) | 0.84 |
| Men | 236 (55.27%) | 120 (54.74%) | 116 (55.77%) | ||
| Performance status (PS) | 0 | 52 (13.4%) | 29 (13.49%) | 23 (13.29%) | 0.04 |
| 1 | 222 (57.22%) | 136 (62.33 %) | 88 (50.87%) | ||
| 2 | 114 (29.38%) | 52 (24.19%) | 62 (35.84%) | ||
| NA | 39 | 4 | 35 | ||
| Stage at diagnosis | Localised | 36 (9.42%) | 26 (11.87%) | 10 (6.13%) | 0.009 |
| Locally advanced | 70 (18.32%) | 48 (21.92%) | 22 (13.5%) | ||
| Metastatic | 276 (72.25%) | 145 (62.21%) | 131 (80.37%) | ||
| NA | 45 | 0 | 45 | ||
| Number of FFX cycles | <4 | 93 (24.47%) | 48 (22.12%) | 45 (27.61%) | 0.001 |
| 4–12 | 205 (53.95%) | 107 (49.31%) | 98 (60.12%) | ||
| >12 | 82 (21.58%) | 62 (28.57%) | 20 (12.27%) | ||
| NA | 47 | 2 | 45 | ||
| Cause of FFX interruption | Disease progression | 310 (89.34%) | 200 (91.32%) | 110 (85.94%) | 0.12 |
| Intolerance/toxicity | 37 (10.66%) | 19 (8.68%) | 18 (14.06%) | ||
| NA | 80 | 80 | |||
| Best response under FFX | Complete response | 1 (0.26%) | 0 (0%) | 1 (0.6%) | <0.001 |
| Partial response | 131 (34.38%) | 53 (24.88%) | 78 (46.43%) | ||
| Stable disease | 110 (28.87%) | 72 (33.8%) | 38 (22.62%) | ||
| Progressive disease | 139 (36.48%) | 88 (41.31%) | 51 (30.36%) | ||
| NA | 46 | 6 | 40 | ||
| Number of metastatic sites | ≤2 | 305 (87.9%) | 186 (84.93%) | 119 (92.97 %) | 0.03 |
| >2 | 42 (12.1%) | 33 (15.07%) | 9 (7.03%) | ||
| NA | 80 | 0 | 80 | ||
| Metastatic sites | Peritoneum | 124 (31.63%) | 89 (40.64%) | 35 (20.23%) | <0.001 |
| Liver | 272 (69.39%) | 156 (71.23%) | 116 (67.05%) | 0.37 | |
| Lung | 81 (23.34%) | 51 (23.29%) | 30 (23.44%) | 0.98 | |
| Bone | 24 (6.92%) | 15 (6.85%) | 9 (7.03%) | 0.95 | |
| Adenopathy | 55 (15.85%) | 50 (22.83%) | 5 (3.91%) | <0.001 | |
| CA19.9 (UI/L) | ≤200 UI/L | 87 (28.62%) | 49 (27.84%) | 38 (29.69%) | 0.73 |
| >200 UI/L | 217 (71.38%) | 127 (72.16%) | 90 (70.31%) | ||
| NA | 123 | 43 | 80 | ||
FFX FOLFIRINOX.